Recommended Free Tools
“Gene dreams troubled by market realities” is the headline of Hepeng Jia’s 31 August 2007 Chemistry World article. Its indexed subtitle describes Chinese gene therapy trials that showed five years of success against cancer. The article page is not accessible, so its full argument about commercial prospects cannot be reconstructed responsibly. The historical record does show how Gendicine became an early gene-therapy milestone—and why reported results, independent evidence appraisal, regulatory approval and commercial success must be kept distinct.
What Gendicine was—and what its approval meant
Gendicine was a recombinant adenovirus designed to deliver the human p53 gene. Contemporary reporting identified its intended use as head and neck squamous cell carcinoma (HNSCC). Shenzhen SiBiono GenTech received a Chinese drug license for that use on 16 October 2003, according to Nature Biotechnology’s 2004 report. A later review says the product entered the commercial market in 2004 (review citation).
As an Amazon Associate I earn from qualifying purchases.
Those are historical milestones, not evidence that Gendicine is authorized or commercially available in China today. The available sources do not establish its current status.
Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Repair Windows errors before they cause bigger problems3Scan for outdated or missing drivers - takes under a minuteWhat the reported response figures do—and do not—show
In 2004, Nature Biotechnology reported that after eight weeks of radiotherapy combined with weekly Gendicine, 64% of patients with late-stage HNSCC had complete tumor regression and 32% had partial regression. These are figures reported in that historical account. They describe a combined regimen, not gene therapy alone, and should not be treated as independently confirmed efficacy or as a current estimate. The cited account does not establish how those outcomes compare with radiotherapy alone.
#1 Best Overall
Why the evidence was contested
A 2005 critical analysis questioned the robustness and transparency of the clinical evidence behind Gendicine’s claims and raised concerns about the developer’s commercial interests (critical analysis citation). That paper is a critique, not a regulator’s determination or a final clinical verdict. Read alongside the contemporary account, it underscores why reported outcomes, independent appraisal and regulatory authorization are separate questions.
Approval did not settle the market question
The 2004 report said SiBiono had spent more than RMB 80 million ($9.6 million) on development, in addition to government research grants. That is a historical figure as reported then; it is not a current cost estimate or a measure of sales, affordability or commercial viability.
Rank #2
The same report quoted then-chairman and CEO Zhaohui Peng saying: “We have had more than five years of clinical trials, and the only side effect of Gendicine is self-limited fever.” This is a company executive’s statement, not an independent safety conclusion.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →The 2007 Chemistry World headline points to market realities, but without access to the article’s full text it is not possible to say what specific commercial obstacles Jia discussed. The sources here also do not establish present-day sales, access or market status.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How Gendicine fits beside H101
A 2006 Nature Medicine report described H101 as another Chinese adenovirus-based cancer therapy approved in 2005. The sources available establish a few historical points, but do not support a fair comparison of clinical performance or commercial outcomes.
Quick Recap
Best Value
| Product | What the cited sources establish | What they do not establish |
|---|---|---|
| Gendicine | Recombinant adenovirus carrying human p53; licensed in China for HNSCC in October 2003, according to the 2004 report. A 2017 review says it entered the market in 2004. | Current authorization or availability; comparative efficacy, safety, affordability, access or present-day sales. |
| H101 | A 2006 report describes it as another Chinese adenovirus-based cancer therapy approved in 2005. | A comparison with Gendicine on clinical outcomes, safety, affordability, access or market performance. |
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
